TRINETRA › Sectors › Healthcare
Bajaj Healthcare Limited (BAJAJHCARE) — share price, P/E and fundamentals
Bajaj Healthcare Limited (NSE: BAJAJHCARE) closed at ₹304.50 on 30 Oct 2026, -35.2% over one year, against a 52-week range of ₹272.35 – ₹488.90.
In the quarter ended 30 Sept 2026 (standalone, filed 17 Oct 2026) it reported revenue of ₹176 cr and net profit of ₹14 cr, a 8.0% net margin; revenue grew 18.9% and profit grew 15.7% year on year.
On four consecutive filed quarters its trailing P/E is 49.7; since 27 May 2025 its own P/E has ranged from 16.8 to 54.8 (median 32.7), and today's reading is higher than 67% of those 353 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 10.1%, ROCE 14.9%, debt-to-equity 0.48, Piotroski F-score 4 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 19% of 64 sector peers; PBT margin higher than 17% of 64 sector peers; ROE higher than 27% of 64 sector peers.
Key figures
| Last close | ₹304.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -13.0% / -6.0% / -35.2% |
| 52-week low – high | ₹272.35 – ₹488.90 |
| Market capitalisation | ₹1,025 cr |
| Trailing P/E | 49.7 |
| Price / book | 1.84 |
| EV / EBITDA | 14.8 |
| Earnings yield | 2.0% |
| TTM EPS | ₹6.12 |
| TTM net profit | ₹21 cr |
| Quarter revenue | ₹176 cr |
| Quarter net profit | ₹14 cr |
| Net margin | 8.0% |
| Revenue growth (YoY) | +18.9% |
| Profit growth (YoY) | +15.7% |
| Return on equity | 10.1% |
| ROCE | 14.9% |
| Debt / equity | 0.48 |
| Current ratio | 1.76 |
| Free cash flow | ₹-45 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹2.9 cr |
Against Healthcare peers
| Metric | BAJAJHCARE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 8.01 | 12.89 | 19 |
| PBT margin | 10.50 | 17.68 | 17 |
| ROE | 10.12 | 13.87 | 27 |
| ROCE | 14.89 | 17.26 | 36 |
| Debt / equity | 0.48 | 0.11 | 88 |
| FCF margin | -13.26 | -0.87 | 13 |
| Cash conversion | 0.56 | 1.25 | 15 |
| Trailing P/E | 49.73 | 43.26 | 55 |
Questions
What is the P/E ratio of Bajaj Healthcare Limited?
Bajaj Healthcare Limited's trailing P/E is 49.7, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 27 May 2025 its P/E has ranged 16.8–54.8.
What were Bajaj Healthcare Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Bajaj Healthcare Limited reported revenue of ₹176 cr and net profit of ₹14 cr (standalone), filed with the exchange on 17 Oct 2026.
What is Bajaj Healthcare Limited's ROE?
Return on equity is 10.1% based on the balance sheet dated 30 Sept 2026.
Does Bajaj Healthcare Limited have debt?
Debt-to-equity is 0.48 on the balance sheet dated 30 Sept 2026.
What is BAJAJHCARE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, BAJAJHCARE traded between ₹272.35 and ₹488.90.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.